Clinical trials: Chest--Diseases
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
The study will contain three stages: Phase I includes dose escalation phase (i.e., phase Ia) and dose expansion phase (i.e., phase Ib).
- Trial name
- NCT06590194
- Testing
- PH009-1 tablet
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD
Malignant Pleural Effusion, Malignant Ascites
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
Malignant pleural effusion and/ or malignant ascites is generally defined by presence of malignant cells in the effusion fluid. The first-line therapies are mostly intrusive, medically demanding and inefficient, and therefore, it…
- Trial name
- NCT03736122
- Testing
- BSG-001
- Where
- Australia
- Volunteers
- 58 people
- Sponsor
- BioSyngen Pte Ltd
Lung Cancer
Safety Evaluation of Dexmedetomidine for EBUS-TBNA
Lung cancer is the second most commonly diagnosed primary neoplasia in Canada accounting for 22 865 new cases in 2007. Recent randomized trials have shown a significantly better diagnostic yield and fewer unnecessary…
- Trial name
- EBUSed (NCT01381627)
- Testing
- Remifentanil, Dexmedetomidine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Raynaud's Phenomenon
MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison
The purpose of this clinical study is to compare the pharmacokinetic profiles of a topical cream formulation of 0.9% nitroglycerin, MQX 503, and Nitroglycerin Ointment 2%, USP.
- Trial name
- NCT00841594
- Testing
- nitroglycerin 0.9 % (MXQ-503), Nitroglycerin ointment 2%, USP
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Lung Cancer
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00984542
- Testing
- bendamustine hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Small Cell Lung Cancer
Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment
The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line…
- Trial name
- TransCPC (NCT03419286)
- Volunteers
- 62 people
- Sponsor
- University Hospital, Grenoble
Coronary Artery Disease, Angina Pectoris
Understanding the Effect of Metformin on Corus CAD (or ASGES)
The study goal was to understand the effect of Metformin on Age/Sex/Gene Expression Score (ASGES) or Corus CAD (henceforth "Corus") in pre-diabetic patients who are medication naive.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- MET (NCT02440893)
- Testing
- Corus CAD (ASGES)
- Volunteers
- 37 people
- Sponsor
- CardioDx
Sleep Disorder, Lung Tumor
Effect of Sleep Disorder on the Development of Lung Tumors
The goal of this observational study is to observe the lung tumor development in lung tumor patients with long-term sleep disorder.
- Trial name
- NCT05745506
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Chest Pain
Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of NSTE-ACS
Rapid and reliable exclusion of acute myocardial infarction (AMI) during an emergency department (ED) triage is a major unmet clinical need.
- Trial name
- COPACS (NCT01962506)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- G. d'Annunzio University
RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic…
- Trial name
- GFH276X1203 (NCT07846358)
- Testing
- GFH276, with or without Tislelizumab, Pemetrexed
- Volunteers
- 84 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Non-small-Cell Lung Carcinoma
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
The primary objective of this study is to assess the response rate of treatment with two cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT00232206
- Testing
- Neoadjuvant Therapy with Cisplatin Plus Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Providence Health & Services
Acute Coronary Syndrome Without ST Elevation on Electrocardiogram, Acute Coronary Syndromes (ACS)
Occurrence of Severe Cardiac Rhythm and Conduction Disturbances in Emergency Department Patients With Non-ST Elevation Acute Coronary Syndrome
Cardiovascular diseases are the leading cause of death worldwide. Among them, coronary artery disease-especially in its acute form, known as acute coronary syndrome (ACS)-is the most frequent cause of cardiovascular death.
- Conditions
- Acute Coronary Syndrome Without ST Elevation on Electrocardiogram, Acute Coronary Syndromes (ACS), Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
- Trial name
- SurvSCA (NCT07112547)
- Where
- 10 sites in France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-II
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-II (NCT03655821)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Radboud University Medical Center
Non Small Cell Lung Cancer
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.
- Trial name
- NCT00456833
- Testing
- RAD001, erlotinib
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasms
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
In non-small celled lung cancer (NSCLC) 10-15% of the patients harbor a mutation in the tumor's epidermal growth factor receptor (EGFR M+). This receptor is the target for treatment with erlotinib.
- Trial name
- NCT02284633
- Where
- Denmark
- Volunteers
- 250 people
- Sponsor
- Aarhus University Hospital
Esophageal Cancer
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer
Most local failures after definitive chemoradiation for unresectable esophageal cancer occur in the gross tumor volume (GTV). And the metabolic active areas post-treatment were located in the high FDG uptake areas prior to the…
- Trial name
- NCT01843049
- Testing
- Radiotherapy, Chemotherapy (5-FU+DDP)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer Stage II, Bevacizumab
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases
- Conditions
- Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases
- Trial name
- SUPER BRAIN (NCT05807893)
- Testing
- Serplulimab combined with bevacizumab and first-line chemotherapy
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Immune-related Colitis
EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
The photoactivating agent UVADEX (methoxsalen) is used in conjunction with extracorporeal photopheresis (ECP) as an immunomodulatory therapy approved for the treatment of cutaneous T-cell lymphoma.
- Trial name
- EPIC (NCT06646016)
- Testing
- Methoxsalen, Infliximab, Vedolizumab
- Where
- United States
- Sponsor
- Therakos LLC
Healthcare Associated Infectious Disease, Sternal Superficial Wound Infection
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Our Aim is to identify patient risk factors and clinical practices associated with healthcare-acquired infections (HAIs) after cardiac surgery.
- Conditions
- Healthcare Associated Infectious Disease, Sternal Superficial Wound Infection, Sepsis, Pneumonia
- Trial name
- HAI (NCT02068716)
- Where
- United States
- Volunteers
- 911,754 people
- Sponsor
- Dr. Donald Likosky
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.